Dr. Catino is a Senior Executive with extensive experience in discovery and early clinical development of small molecules, protein therapeutics and gene therapy agents. He spent 28 years in large pharmaceutical companies rising from an entry level scientist in the oncology section of Bristol Myers, to Senior Vice President of Discovery Research, Preclinical Development and Early Clinical Development at Bayer Corporation.
In the latter role, Dr. Catino was a member of the US Executive Leadership Team, the International R&D Management Team and the Global Leadership Circle. He chaired the US patent committee and licensing committee. In 2008, Dr. Catino established an independent consulting company, Oaklee Consulting LLC, from which he has served large, mid-sized and small companies in the pharmaceutical and biotechnology space over the past 12 years. In 2009 Dr. Catino teamed with Yale University faculty to launch Helix Therapeutics, a gene editing company using triplex forming oligonucleotide technology.